The ESMO guidelines working group would like to publish the following corrections to manuscripts published in 2012/2013

摘要

Ann Oncol (2012) 23 (suppl 7): vii33-vii40. In the section on Treatment in Stage IV, in the second paragraph it is stated: "A recent phase III trial using a combination of 5-FU, irinotecan and oxaliplatin (FOLFIRINOX) has shown a response rate of 31.6%, a median survival of 11.1 months (hazard ratio 0.57, 95% confidence interval 0.45 -0.73), and 1-year survival rate of 48.4% in the FOLFIRINOX arm [29]. FOLFIRINOX also delayed deterioration of quality of life. In this trial, patients >75 years were excluded and eligibility was restricted to PS 0 and 1.60% of patients had cancers of the body and tail of pancreas." The last sentence of this extract should read: "In this trial, patients >75 years were excluded and eligibility was restricted to PS 0 and 58.7% of patients had cancers of the body and tail of pancreas." Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol (2012) 23 (suppl 7): vii65-vii71. In the section on Management of Metastatic Disease, under the heading "First-line treatment for patients with prognosis" should read "First-line treatment for patients with poor prognosis". Figure 1. The following corrections to levels of evidences and grades of recommendations should be noted: First-line treatment: Clear-cell histology: Good/intermediate prognosis: Bevacizumab + interferon-a (IA) First-line treatment: Clear-cell histology: Good/intermediate prognosis: Pazopanib (IIB) First-line treatment: Clear-cell histology: Poor prognosis: Temsirolimus (IB) Figure 2. The following corrections to levels of evidences and grades of recommendations should be noted: Second line treatment: Previous treatment with a VEGF(Rs)-pathway inhibitor: Axitinib (IB)